#Vagal #nerve #stimulation Hand held device #BDMARD failure Plausible - improved pro inflammatory cytokines wears off benefit if stopped Attenuates in ~half over yrs Open label uncontrolled @RheumNow @eular_org #EULAR2025 Session D2T-RA https://t.co/98K5gwasHv

• https://x.com/Janetbirdope/status/1933173694483857658/photo/1
• https://x.com/Janetbirdope/status/1933173694483857658/photo/1
• https://x.com/Janetbirdope/status/1933173694483857658/photo/1

Study on the HLAs associated with the occurrence and course of acute/tender dactylitis in PsA patients. Acute dactylitis genetics: •HLA-B27 (OR 1.71), HLA-C12 (OR 1.43), B38/C12 & B27/C02 haplotypes. •Resolution faster on b/tsDMARDs (HR 1.67); unaffected by HLA. Abstract

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j

#RITAZAREM: infection risk during RTX induction in AAV was ↑ w/ lung disease & nodules/cavities; ↓ w/ TMP-SMX prophylaxis. Early infections predicted later ones, but risk didn’t differ by RTX vs AZA. Pulmonary damage is a key red flag for infection @RheumNow #EULAR2025 #OP0167

#D2T #RA ~20% #Polyrefractory 3% Many reasons for d/c ing #Rx - D2T AEs Intolerance Chronic pain Etc My approach is different depending on reasons why drugs were d/c Ie ?obj inflammation vs pain or intolerance @RheumNow @eular_org #EULAR2025 #whatmakes D2T RA difficult https://t.co/AL6TMVJIk9

• https://x.com/Janetbirdope/status/1933161013836226975/photo/1

In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity. CKD stage ≥3 doubled HCQ levels at same dose. Supports monitoring & dose adjustment in CKD to balance safety & efficacy. @RheumNow #EULAR2025 #OP0199

Combination of LEF and MTX in RA: Yay or Nay? #EULAR2025 @RheumNow

OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025

ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/ PPV-23 helped a few but 48% failed to mount robust response. Time to rethink vaccine strategies in RTX-treated patients? @RheumNow #EULAR2025 #OP0173 https://t.co/soU5qfwRib

• https://x.com/DrMiniDey/status/1933097191532585263/photo/1

2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals. @RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF

• https://x.com/DrMiniDey/status/1933080330883453155/photo/1

In SLEek LTE, ABBV-599 HD (BTKi+JAKi) & UPA 30mg sustained or improved disease control through 104wks: SRI-4 ≥82%, ↓flares, near steroid-free, no new safety signals. PBO-switchers improved too. Targeted oral combos look promising. @RheumNow #EULAR2025 #OP0198 https://t.co/IHXC2iD0h6

• https://x.com/DrMiniDey/status/1933081588700439034/photo/1

#Oninutuzumab works in #lupus #nephritis #LN no matter how you vary the #renal #responses Of various definitions of #Complete & #Partial #renal #responses abst#OP0006 #EULAR25 @eular_org @RheumNow Not surprised 😲 https://t.co/Zn2lXkddez

• https://x.com/Janetbirdope/status/1932879643616456951/photo/1
• https://x.com/Janetbirdope/status/1932879643616456951/photo/1

Precision immunotherapy in axial spondyloarthritis: TRBV9xCD3 bispecific antibodies selectively depleted autoreactive TRBV9+ T cells from HLA-B27+ AS patient samples while sparing over 95 percent of the T cell repertoire. TRBV9xCD3 bispecific antibodies selectively depleted https://t.co/8UXqEaDYnS

• https://x.com/synovialjoints/status/1932917464574406770/photo/1